Correlated Drug Terms (2)

---

	Name (Synonyms)	Correlation
drug3293	hyperbaric oxygen therapy (HBOT) Wiki	1.00
drug2122	Placebo Wiki	0.05

Correlated MeSH Terms (1)

---

	Name (Synonyms)	Correlation
D018352	Coronavirus Infections NIH	0.04

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: DLT will be assessed by DAIDS v2.1. The measurements include clinical symptoms and abnormal vital signs, abnormal laboratory tests (complete blood cell count, serum chemistry, routine urinalysis, coagulation function, etc.) and 12-lead ECGs

Measure: Dose-limiting toxicity(DLT)

Time: 7 days

---

Description: MTD will be assessed by DAIDS v2.1. The measurements include clinical symptoms and abnormal vital signs, abnormal laboratory tests (complete blood cell count, serum chemistry, routine urinalysis, coagulation function, etc.) and 12-lead ECGs.

Measure: Maximal Tolerable Dose(MTD)

Time: 12 weeks

---

Secondary Outcomes

Description: Area under the curve from the time of dosing to the last measurable concentration time t (AUC0-t)

Measure: AUC0-t

Time: 12 weeks

---

Description: Area Under the Concentration Time Curve (AUC) From Time Zero to Infinity (AUC 0-∞)

Measure: AUC0-∞

Time: 12 weeks

---

Description: Elimination Phase Half-life(t1/2)

Measure: t1/2

Time: 12 weeks

---

Description: Time to the Maximum Concentration(Tmax)

Measure: Tmax

Time: 12 weeks

---

Description: Positive rate of anti-SCT A01 antibody

Measure: Anti-drug antibody(ADA)

Time: 12 weeks

---

Description: Adverse events as assessed by DAIDS v2.1, including clinical symptoms and abnormal vital signs, abnormal laboratory tests (complete blood cell count, serum chemistry, routine urinalysis, coagulation function, etc.) and 12-lead ECGs

Measure: Adverse events

Time: 12 weeks

---